Literature DB >> 27090599

Differential radiologic characteristics of renal tumours on multiphasic computed tomography.

Boon Chye Ching1, Hui Shan Tan2, Puay Hoon Tan3, Chee Keong Toh2, Ravindran Kanesvaran2, Quan Sing Ng2, Min Han Tan2.   

Abstract

INTRODUCTION: This study analysed the tumour attenuation characteristics of different subtypes of renal cell carcinomas (RCCs), including clear cell RCC (ccRCC), papillary RCC (pRCC), mixed RCC, chromophobe RCC (chRCC) and oncocytoma.
METHODS: We randomly selected 100 RCC cases that underwent nephrectomy between 2004 and 2012 from a collaborative database. Of these cases, 36 were excluded due to the absence of available imaging. The remaining 64 cases comprised 35 ccRCCs, 11 pRCCs, eight chRCCs, seven mixed RCCs and three oncocytomas. The cases were classified as computed tomography (CT) kidney, CT urogram (with plain, nephrographic and pyelographic phases) or CT abdomen (with portovenous and delayed phases). A circular region of interest (ROI) ≥ 1 cm2 was drawn and the same standard ROI size was used for each phase at the same site; three different circular ROIs were drawn per lesion per phase. Analysis of variance and t-test were used to examine differences in the radiological characteristics.
RESULTS: There was no statistical difference in the attenuation and degree of enhancement between mixed RCCs and ccRCCs. The attenuation and degree of enhancement of the oncocytomas were significantly higher than those of the other RCC subtypes.
CONCLUSION: While mixed RCCs did not have attenuation characteristics that differed significantly from those of ccRCCs, oncocytomas can be distinguished from ccRCCs, pRCCs, chRCCs and mixed RCCs by their high radiological density and enhancement. The ability to differentiate oncocytomas from these tumours potentially allows the preoperative selection of patients with small renal masses for conservative management. Copyright: © Singapore Medical Association

Entities:  

Keywords:  attenuation; clear cell renal cell carcinoma; enhancement; radiodensity; renal cell carcinoma

Mesh:

Year:  2016        PMID: 27090599      PMCID: PMC5435845          DOI: 10.11622/smedj.2016081

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  18 in total

1.  Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomes.

Authors:  Jeffrey A Leslie; Tom Prihoda; Ian M Thompson
Journal:  Urol Oncol       Date:  2003 Jan-Feb       Impact factor: 3.498

Review 2.  The pathology of renal epithelial neoplasms.

Authors:  Victor E Reuter
Journal:  Semin Oncol       Date:  2006-10       Impact factor: 4.929

3.  Renal cell carcinoma in adults 40 years old or less: young age is an independent prognostic factor for cancer-specific survival.

Authors:  Xavier Taccoen; Antoine Valeri; Jean-Luc Descotes; Vincent Morin; Eric Stindel; Laurent Doucet; Vincent Joulin; Frederic Bocqueraz; Christian Coulange; Jean-Jacques Rambeaud; Georges Fournier; Arnaud Mejean
Journal:  Eur Urol       Date:  2006-10-25       Impact factor: 20.096

4.  Differentiation of oncocytoma and renal cell carcinoma in small renal masses (<4 cm): the role of 4-phase computerized tomography.

Authors:  Vincent G Bird; Prashanth Kanagarajah; Gaston Morillo; Daniel J Caruso; Rajinikanth Ayyathurai; Raymond Leveillee; Merce Jorda
Journal:  World J Urol       Date:  2010-08-18       Impact factor: 4.226

5.  Small renal oncocytomas: differentiation with multiphase CT.

Authors:  Georgios Gakis; Ulrich Kramer; David Schilling; Stephan Kruck; Arnulf Stenzl; Hans-Peter Schlemmer
Journal:  Eur J Radiol       Date:  2010-07-27       Impact factor: 3.528

6.  Overweight and obesity in adults and risk of renal cell carcinoma in Canada.

Authors:  Jinfu Hu; Yang Mao; Kathy White
Journal:  Soz Praventivmed       Date:  2003

7.  Chromophobe renal cell carcinoma: multiphase MDCT enhancement patterns and morphologic features.

Authors:  Siva P Raman; Pamela T Johnson; Mohamad E Allaf; George Netto; Elliot K Fishman
Journal:  AJR Am J Roentgenol       Date:  2013-12       Impact factor: 3.959

8.  Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer.

Authors:  Hersh Chandarana; Andrew B Rosenkrantz; Thais C Mussi; Sooah Kim; Afshan A Ahmad; Sean D Raj; John McMenamy; Jonathan Melamed; James S Babb; Berthold Kiefer; Atilla P Kiraly
Journal:  Radiology       Date:  2012-12       Impact factor: 11.105

9.  Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma.

Authors:  Frank Chen; Hannu Huhdanpaa; Bhushan Desai; Darryl Hwang; Steven Cen; Andy Sherrod; Jean-Christophe Bernhard; Mihir Desai; Inderbir Gill; Vinay Duddalwar
Journal:  Springerplus       Date:  2015-02-10

10.  Uselessness of radiological differentiation of oncocytoma and renal cell carcinoma in management of small renal masses.

Authors:  Teresa Pusiol; Maria Grazia Zorzi; Doriana Morichetti; Irene Piscioli; Michele Scialpi
Journal:  World J Urol       Date:  2011-05-21       Impact factor: 4.226

View more
  3 in total

Review 1.  Renal Oncocytoma: The Diagnostic Challenge to Unmask the Double of Renal Cancer.

Authors:  Francesco Trevisani; Matteo Floris; Roberto Minnei; Alessandra Cinque
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

2.  Multidetector CT Characteristics of Fumarate Hydratase-Deficient Renal Cell Carcinoma and Papillary Type II Renal Cell Carcinoma.

Authors:  Ling Yang; Xue-Ming Li; Ya-Jun Hu; Meng-Ni Zhang; Jin Yao; Bin Song
Journal:  Korean J Radiol       Date:  2021-09-24       Impact factor: 3.500

3.  Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings.

Authors:  Anna K Paschall; Moozhan Nikpanah; Faraz Farhadi; Elizabeth C Jones; Paul G Wakim; Andrew J Dwyer; Rabindra Gautam; Maria J Merino; Ramaprasad Srinivasan; W Marston Linehan; Ashkan A Malayeri
Journal:  Clin Imaging       Date:  2020-06-09       Impact factor: 1.605

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.